PTPRC and neoplasm: IF-IHC demonstrated that co-expression of intracellular Rab37 and IL-6 with tumor-infiltrating CD45+ immune cells (CD45+Rab37+IL-6+) was observed especially in late stage patients (Figure S6A-B).